Megan E V Caram1,2, Mary K Oerline3, Stacie Dusetzina4, Lindsey A Herrel3, Parth K Modi3, Samuel R Kaufman3, Ted A Skolarus2,3, Brent K Hollenbeck3, Vahakn Shahinian1,3. 1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan. 2. Ann Arbor VA Center for Clinical Management Research, VA Health Services Research and Development, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. 3. Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan. 4. Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
BACKGROUND: Abiraterone and enzalutamide are high-cost oral therapies that increasingly are used to treat patients with advanced prostate cancer; these agents carry the potential for significant financial consequences to patients. In the current study, the authors investigated coping and material measures of the financial hardship of these therapies among patients with Medicare Part D coverage. METHODS: The authors performed a retrospective cohort study on a 20% sample of Medicare Part D enrollees who underwent treatment with abiraterone or enzalutamide between July 2013 and June 2015. The authors described the variability in adherence rates and out-of-pocket payments among hospital referral regions in the first 6 months of therapy and determined whether adherence and out-of-pocket payments were associated with patient factors and the socioeconomic characteristics of where a patient was treated. RESULTS: There were 4153 patients who filled abiraterone or enzalutamide prescriptions through Medicare Part D in 228 hospital referral regions. The mean adherence rate was 75%. The median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range, $0-$3505). After multilevel, multivariable adjustment for patient and regional factors, adherence was found to be lower in patients who were older (69% for patients aged ≥85 years vs 76% for patients aged <70 years; P < .01) and in those with low-income subsidies (69% in those with a subsidy vs 76% in those without a subsidy; P < .01). Both Hispanic ethnicity and living in a hospital referral region with a higher percentage of Hispanic beneficiaries were found to be independently associated with higher out-of-pocket payments for abiraterone and enzalutamide. CONCLUSIONS: There were substantial variations in the adherence rate and out-of-pocket payments among Medicare Part D beneficiaries who were prescribed abiraterone and enzalutamide. Sociodemographic patient and regional factors were found to be associated with both adherence and out-of-pocket payments.
BACKGROUND: Abiraterone and enzalutamide are high-cost oral therapies that increasingly are used to treat patients with advanced prostate cancer; these agents carry the potential for significant financial consequences to patients. In the current study, the authors investigated coping and material measures of the financial hardship of these therapies among patients with Medicare Part D coverage. METHODS: The authors performed a retrospective cohort study on a 20% sample of Medicare Part D enrollees who underwent treatment with abiraterone or enzalutamide between July 2013 and June 2015. The authors described the variability in adherence rates and out-of-pocket payments among hospital referral regions in the first 6 months of therapy and determined whether adherence and out-of-pocket payments were associated with patient factors and the socioeconomic characteristics of where a patient was treated. RESULTS: There were 4153 patients who filled abiraterone or enzalutamide prescriptions through Medicare Part D in 228 hospital referral regions. The mean adherence rate was 75%. The median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range, $0-$3505). After multilevel, multivariable adjustment for patient and regional factors, adherence was found to be lower in patients who were older (69% for patients aged ≥85 years vs 76% for patients aged <70 years; P < .01) and in those with low-income subsidies (69% in those with a subsidy vs 76% in those without a subsidy; P < .01). Both Hispanic ethnicity and living in a hospital referral region with a higher percentage of Hispanic beneficiaries were found to be independently associated with higher out-of-pocket payments for abiraterone and enzalutamide. CONCLUSIONS: There were substantial variations in the adherence rate and out-of-pocket payments among Medicare Part D beneficiaries who were prescribed abiraterone and enzalutamide. Sociodemographic patient and regional factors were found to be associated with both adherence and out-of-pocket payments.
Authors: Nicholas R Faris; Matthew P Smeltzer; Fujin Lu; Carrie L Fehnel; Nibedita Chakraborty; Cheryl L Houston-Harris; E Todd Robbins; Raymond S Signore; Laura M McHugh; Bradley A Wolf; Lynn Wiggins; Paul Levy; Vishal Sachdev; Raymond U Osarogiagbon Journal: Semin Thorac Cardiovasc Surg Date: 2016-10-14
Authors: Thomas G Knight; Allison M Deal; Stacie B Dusetzina; Hyman B Muss; Seul Ki Choi; Jeannette T Bensen; Grant R Williams Journal: J Oncol Pract Date: 2018-10-24 Impact factor: 3.840
Authors: Yi-Ting Chou; Joel F Farley; Thomas E Stinchcombe; Amber E Proctor; Jennifer Elston Lafata; Stacie B Dusetzina Journal: J Natl Cancer Inst Date: 2020-06-01 Impact factor: 13.506
Authors: Veena Shankaran; Hannah Linden; Jordan Steelquist; Kate Watabayashi; Karma Kreizenbeck; Tony Leahy; Karen Overstreet Journal: Am J Manag Care Date: 2017-03 Impact factor: 2.229
Authors: Veena Shankaran; Joseph M Unger; Amy K Darke; Jennifer Marie Suga; James L Wade; Peter J Kourlas; Sreenivasa R Chandana; Mark A O'Rourke; Suma Satti; Diane Liggett; Dawn L Hershman; Scott D Ramsey Journal: J Natl Cancer Inst Date: 2022-03-08 Impact factor: 13.506
Authors: Nancy L Keating; Gabriel A Brooks; Mary Beth Landrum; Pang-Hsiang Liu; Robert Wolf; Lauren E Riedel; Nirav S Kapadia; Shalini Jhatakia; Amanda Tripp; Carol Simon; Van Doren Hsu; Colleen M Kummet; Andrea Hassol Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816